echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > AP-T: A decrease in hepatitis B virus RNA and a decrease in non-viral antigens was associated with a low probability of continuous response and loss of surface antigens in hepatitis B

    AP-T: A decrease in hepatitis B virus RNA and a decrease in non-viral antigens was associated with a low probability of continuous response and loss of surface antigens in hepatitis B

    • Last Update: 2021-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Chronic hepatitis B (CHB) infection is one of the main causes of end-stage liver disease and hepatocellular carcinoma (HCC).
    the best goal of antiviral therapy is to achieve a continuous post-drug response to reduce the incidence of HCC and limit the progression of liver disease.
    , however, it is still difficult to achieve because co-priced closed ring DNA (cccDNA) of the hepatitis B virus (HBV) is still present in liver cells.
    despite the emergence of new compounds, current treatment options are limited to nucleotide analogophobics (NAs) and polyglycolin interferons (PEG-IFN).
    nucleoside analogs have good tolerance and can effectively inhibit HBV replication.
    , however, nucleotide analogophobics do not directly affect cccDNA, so the continuous response rate after treatment is limited.
    the elimination of cccDNA in liver cells is considered a key step in the removal of the hepatitis B virus (HBV), there is a strong need to monitor drug dynamics during treatment.
    , however, cccDNA can only be accurately and invasly quantified through liver biopsies.
    , it is clinically necessary to use non-invasive serological markers associated with the replication activity in the HBV liver to assess the efficacy of antiviral drugs in CHB patients.
    New antiviral drugs showed a decline in RNA in effective HBV and no decrease in hepatitis B surface antigens (HBsAg), and the researchers conducted a study to study the extent to which viral antigens declined in treatment with patients with continuous post-treatment response and HBsAg loss and HBV RNA decline.
    patients with chronic hepatitis B who were treated with polyglycol interferon, the researchers quantitatively tested their HBV RNA, HBsAg and hepatitis B core-related antigens (HBcrAg).
    to assess continuous responses (HBV DNA slt;2000 IU / mL) and/or HBsAg loss in patients with or without treatment for HBV RNA responses 2 log HBV RNA drop or 1 log drop) and the HBsAg drop is layered according to .lt;0.5, 0.5-1, and 1 log.
    the study recruited a total of 279 patients; 176 positive hepatitis B e antigen (HBeAg) and 103 HBeAg negative.
    20.4% of patients achieved continuous remission.
    in the 24th week of treatment, the HBV RNA response was associated with a higher sustained response rate (27.4% VS non-responders 13.0%, P=0.004).
    , however, in patients with an HBV RNA response (n s 135), 56.4% of patients had no HBsAg drop.
    in HBV RNA respondents, 47.6% of patients with HBsAg declined by 1 log (n s 20/42) achieved a continuous response, while a decrease of 0.5 log (n s 12/75, P s 0.001) was only 16.0%.
    study found that many patients who experienced HBV RNA reactions during treatment based on polyglycol interferon did not experience HBsAg and/or HBcrAg decline.
    the accompanying decline in these viral antigen deficiencies is associated with low treatment response rates and HBsAg loss.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.